Novel screening approach for developing new stable biotherapeutic formulations

Lead Participant: Arecor Limited


A growing number of drugs that are being developed to combat infection and disease are protein based "biotherapeutics". The supply of these vital biotherapeutics is limited only to areas where there is a sufficient cold-chain i.e. fridges/freezers. Arecor is a biotherapeutic formulation company that has developed technology to stabilise liquid formulations to improve their shelf life. In collaboration with Manchester University's Centre of Excellence in Biopharmaceuticals, Arecor will use the TSB formulated product grant to fund the development of the next generation liquid biotherapeutic formulations that are room temperature stable starting with a new room temperature stable formulation of fast acting insulin. These new biotherapeutic formulations can be shipped to any part of the world without the need for cold-chain storage. Unilever, Lilly and PrismTC will all assist in the development of this new technology that will improve healthcare provision to the third world and reduce the environmental burden of cold-chain provision.

Lead Participant

Project Cost

Grant Offer

Arecor Limited, Cambridge, United Kingdom £777,227 £ 466,338


The Victoria University of Manchester £157,479 £ 157,479


10 25 50